Abstract
The therapy of IgA nephropathy (IgAN) is cause for debate among nephrologists. Since the early 1980s, many therapeutic attempts have been proposed, but most of them did not prove efficacy. The recent KDIGO Clinical Practice Guideline for Glomerulonephritis recommend long-term ACE-I or ARB treatment when proteinuria is more than 1 g/day, with up-titration of the drug. For patients with GFR >50 ml/min and proteinuria persistently higher than 1 g/day, they suggest a 6-month course of corticosteroid therapy. Based on our experience and the results of the literature, we propose a progressive treatment, which takes into account the time the IgAN is recognized and the clinical conditions present at that time. The treatment can be summarize as follows: (1) in patients with macro-microscopic haematuria, in case with proteinuria less than 0.3 g/day, only annual controls; (2) in patients with proteinuria between 0.3 and 0.9 g/day, ACE-I and/or ARB, with titration of the drugs; (3) in patients with proteinuria higher than 1 g/day, in case with the presence of arterial hypertension and GFR up to 30 ml/min, 6 months course of corticosteroids, in addition to ACE-I and/or ARB; (4) in patients with GFR less than 30 ml/min, ACE-I/ARB, dialysis and kidney transplantation; corticosteroids should be in case considered for patients with persistently high or increasing proteinuria; (5) the immunosuppressants (cyclophosphamide and azathioprine) should be reserved for patients with progressive renal insufficiency or with vasculitic lesions on renal biopsy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
KDIGO clinical practice guidelines for glomerulonephritis (2012) Chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl 2:S209–S217
Berger J, Hinglais N (1968) Le depots intercapillaire d’IgA-IgG. J Urol Nephrol 74:694–695
Chauveau D, Droz D (1993) Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 104:1–5
Appel GB (2006) To treat or not to treat IgA nephropathy? That is the question! Clin J Am Soc Nephrol 1:347–348
Coppo R, Peruzzi L, Amore A et al (2007) IgACE: a placebo controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888
Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353(9156):883–887
Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15(1):157–163
Lv J, Zhang H, Chen Y et al (2009) Combination therapy of prednisolone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53:26–32
Manno C, Torres DD, Rossini M et al (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694–3701
Ballardie FW, Roberts ISD (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148
Tang SCW, Tang AWC, Wong SSH et al (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77(6):543–549
Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21(10):1783–1790
Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi GB, Pecchini P, Del Vecchio L, Rustichelli R, Semeraro L, Locatelli F (2013) IgA nephropathy with severe chronic renal failure: a randomized controller trial with corticosteroids and azathioprine. J Nephrol 26:86–93
Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C (2015) Changes in proteinuria and side effects of steroids alone or in combination with azathioprine at different stages of IgA nephropathy (submitted)
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39(Suppl 1):S1–S246
Reich HN, Troyanov S, Scholey JW, Cattran D, For the Toronto Glomerulonephritis Registry (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183
Sarcina C, Tinelli C, Ferrario F, Visciano B, Pani A, De Silvestri A, Fogazzi GB, Del Vecchio L, Terraneo V, Furiani S, Santagostino G, Corghi E, Pozzi C (2015) Corticosteroid treatment influences TA-proteinuria and renal survival in IgA nephropathy (submitted)
Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts ISD, Cattran D, Coppo R, On behalf of the VALIGA Study of ERA-EDTA Immunonephrology Working Group (2015) Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 26:2248–2258
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The Author declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Pozzi, C. Treatment of IgA nephropathy. J Nephrol 29, 21–25 (2016). https://doi.org/10.1007/s40620-015-0248-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-015-0248-3